CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today Biogen Idec (NASDAQ: BIIB) reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has determined that dimethyl fumarate in TECFIDERA qualifies as a new active substance (NAS). This designation will provide 10 years of regulatory exclusivity for TECFIDERA in the European Union (EU).
Help employers find you! Check out all the jobs and post your resume.
